A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 24 Nov 2017 Status changed from not yet recruiting to recruiting.
- 07 Sep 2017 Status changed from planning to not yet recruiting.
- 24 May 2017 New trial record